reported that AXL activated its downstream kinases AKT and ERK to maintain sunitinib resistance in RCC.[57] Apart from this, there must be other novel downstream target proteins of STAMBPL1/AXL contributing to the regulation of sunitinib sensitivity in KIRC. This evidence concerns the gene AKT1 and renal cell carcinoma.